The goal of this clinical research study is to learn if the use of molecular testing on tumors can improve response to treatment in patients with triple-negative breast cancer (TNBC) by guiding patients with chemotherapy-sensitive tumors to receive standard chemotherapy and chemotherapy-insensitive tumors to consider a clinical trial. Researchers want to compare the outcome of a study group which receive results of these tests with a group of patients who do not receive the results.